Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience

MLA

M M, Aw, et al. “Basiliximab (Simulect) for the Treatment of Steroid-Resistant Rejection in Pediatric Liver Transpland Recipients: A Preliminary Experience.” Transplantation, vol. 75, no. 6, Mar. 2003. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........4d104c94fff6459151316b6dbcad2740&authtype=sso&custid=ns315887.

APA

M M, A., R M, T., A, V., A, P., A J, B., D, H., P, M., M, R., N D, H., G, M.-V., & A, D. (2003). Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation, 75(6).

Chicago

M M, Aw, Taylor R M, Verma A, Parke A, Baker A J, Hadzic D, Muiesan P, et al. 2003. “Basiliximab (Simulect) for the Treatment of Steroid-Resistant Rejection in Pediatric Liver Transpland Recipients: A Preliminary Experience.” Transplantation 75 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........4d104c94fff6459151316b6dbcad2740&authtype=sso&custid=ns315887.